A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
Completed · NCT05444972
Conditions: Myelofibrosis
At a glance
- Research payments reported, 2025
- $9,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 998
About the trial
- Sponsor
- AbbVie
- Dates
- Started 2022-08-23; completion 2023-11-14
- Results posted
- Not yet
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis. Data from approximately 1000 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks. There is no additional bu…
From ClinicalTrials.gov, last updated 2023-12-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,500 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gabrail Cancer Center Research $9,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.